Efficacy of substituted 9-aminoacridine derivatives in small cell lung cancer

Etchison Ryan, Blake A Jacobson, A. Benoit, David M Ferguson, A. Kratzke Robert

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Summary: Topoisomerase II (TopoII) plays a critical role in the processes of replication, transcription, and decantenation in the cell and is an important chemotherapeutic target in the treatment of small cell lung cancer (SCLC). Current treatment strategies for SCLC employ the use of topoII poisons which stabilize the topoII-DNA transient covalent complex, inducing double stranded DNA damage and cellular death via apoptosis in cancer cells. Despite their effectiveness the topoII poisons are known to induce secondary malignancies in a small population of patients, stimulating the search for new compounds with less toxicity. Recently a small library of substituted 9-aminoacridine derivatives was discovered that displayed topoII catalytic inhibitory properties. In this work we assess their ability to inhibit proliferation and induce cellular death in SCLC. The results indicate effective inhibition of cellular proliferation at EC(50) values in the low μM range. Western blot analysis of p62/LC3 levels, the AKT/mTOR pathway, and the ERK1/2 pathway indicate that autophagy is occurring as the primary mechanism of cell death; furthermore, the Guava Nexin and caspase 3/7 activation assays indicate that apoptosis does not occur. While it is unlikely that the active concentration of these compounds could be achieved in vivo, they show great promise for the use and effectiveness of acridine derivatives in the treatment of SCLC in the future.

Original languageEnglish (US)
Pages (from-to)285-292
Number of pages8
JournalInvestigational New Drugs
Volume31
Issue number2
DOIs
StatePublished - Apr 1 2013

Fingerprint

Aminacrine
Small Cell Lung Carcinoma
Poisons
Cell Proliferation
Psidium
Apoptosis
Acridines
Caspase 7
Type II DNA Topoisomerase
MAP Kinase Signaling System
DNA
Autophagy
Caspase 3
DNA Damage
Libraries
Neoplasms
Cell Death
Therapeutics
Western Blotting
Population

Keywords

  • 9-aminoacridine derivative
  • Catalytic inhibitor
  • Small cell lung cancer
  • Topoisomerase II

Cite this

Efficacy of substituted 9-aminoacridine derivatives in small cell lung cancer. / Ryan, Etchison; Jacobson, Blake A; Benoit, A.; Ferguson, David M; Robert, A. Kratzke.

In: Investigational New Drugs, Vol. 31, No. 2, 01.04.2013, p. 285-292.

Research output: Contribution to journalArticle

Ryan, Etchison ; Jacobson, Blake A ; Benoit, A. ; Ferguson, David M ; Robert, A. Kratzke. / Efficacy of substituted 9-aminoacridine derivatives in small cell lung cancer. In: Investigational New Drugs. 2013 ; Vol. 31, No. 2. pp. 285-292.
@article{638643aff2224a05b79ae78b1934f217,
title = "Efficacy of substituted 9-aminoacridine derivatives in small cell lung cancer",
abstract = "Summary: Topoisomerase II (TopoII) plays a critical role in the processes of replication, transcription, and decantenation in the cell and is an important chemotherapeutic target in the treatment of small cell lung cancer (SCLC). Current treatment strategies for SCLC employ the use of topoII poisons which stabilize the topoII-DNA transient covalent complex, inducing double stranded DNA damage and cellular death via apoptosis in cancer cells. Despite their effectiveness the topoII poisons are known to induce secondary malignancies in a small population of patients, stimulating the search for new compounds with less toxicity. Recently a small library of substituted 9-aminoacridine derivatives was discovered that displayed topoII catalytic inhibitory properties. In this work we assess their ability to inhibit proliferation and induce cellular death in SCLC. The results indicate effective inhibition of cellular proliferation at EC(50) values in the low μM range. Western blot analysis of p62/LC3 levels, the AKT/mTOR pathway, and the ERK1/2 pathway indicate that autophagy is occurring as the primary mechanism of cell death; furthermore, the Guava Nexin and caspase 3/7 activation assays indicate that apoptosis does not occur. While it is unlikely that the active concentration of these compounds could be achieved in vivo, they show great promise for the use and effectiveness of acridine derivatives in the treatment of SCLC in the future.",
keywords = "9-aminoacridine derivative, Catalytic inhibitor, Small cell lung cancer, Topoisomerase II",
author = "Etchison Ryan and Jacobson, {Blake A} and A. Benoit and Ferguson, {David M} and Robert, {A. Kratzke}",
year = "2013",
month = "4",
day = "1",
doi = "10.1007/s10637-012-9854-2",
language = "English (US)",
volume = "31",
pages = "285--292",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "2",

}

TY - JOUR

T1 - Efficacy of substituted 9-aminoacridine derivatives in small cell lung cancer

AU - Ryan, Etchison

AU - Jacobson, Blake A

AU - Benoit, A.

AU - Ferguson, David M

AU - Robert, A. Kratzke

PY - 2013/4/1

Y1 - 2013/4/1

N2 - Summary: Topoisomerase II (TopoII) plays a critical role in the processes of replication, transcription, and decantenation in the cell and is an important chemotherapeutic target in the treatment of small cell lung cancer (SCLC). Current treatment strategies for SCLC employ the use of topoII poisons which stabilize the topoII-DNA transient covalent complex, inducing double stranded DNA damage and cellular death via apoptosis in cancer cells. Despite their effectiveness the topoII poisons are known to induce secondary malignancies in a small population of patients, stimulating the search for new compounds with less toxicity. Recently a small library of substituted 9-aminoacridine derivatives was discovered that displayed topoII catalytic inhibitory properties. In this work we assess their ability to inhibit proliferation and induce cellular death in SCLC. The results indicate effective inhibition of cellular proliferation at EC(50) values in the low μM range. Western blot analysis of p62/LC3 levels, the AKT/mTOR pathway, and the ERK1/2 pathway indicate that autophagy is occurring as the primary mechanism of cell death; furthermore, the Guava Nexin and caspase 3/7 activation assays indicate that apoptosis does not occur. While it is unlikely that the active concentration of these compounds could be achieved in vivo, they show great promise for the use and effectiveness of acridine derivatives in the treatment of SCLC in the future.

AB - Summary: Topoisomerase II (TopoII) plays a critical role in the processes of replication, transcription, and decantenation in the cell and is an important chemotherapeutic target in the treatment of small cell lung cancer (SCLC). Current treatment strategies for SCLC employ the use of topoII poisons which stabilize the topoII-DNA transient covalent complex, inducing double stranded DNA damage and cellular death via apoptosis in cancer cells. Despite their effectiveness the topoII poisons are known to induce secondary malignancies in a small population of patients, stimulating the search for new compounds with less toxicity. Recently a small library of substituted 9-aminoacridine derivatives was discovered that displayed topoII catalytic inhibitory properties. In this work we assess their ability to inhibit proliferation and induce cellular death in SCLC. The results indicate effective inhibition of cellular proliferation at EC(50) values in the low μM range. Western blot analysis of p62/LC3 levels, the AKT/mTOR pathway, and the ERK1/2 pathway indicate that autophagy is occurring as the primary mechanism of cell death; furthermore, the Guava Nexin and caspase 3/7 activation assays indicate that apoptosis does not occur. While it is unlikely that the active concentration of these compounds could be achieved in vivo, they show great promise for the use and effectiveness of acridine derivatives in the treatment of SCLC in the future.

KW - 9-aminoacridine derivative

KW - Catalytic inhibitor

KW - Small cell lung cancer

KW - Topoisomerase II

UR - http://www.scopus.com/inward/record.url?scp=84879555723&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879555723&partnerID=8YFLogxK

U2 - 10.1007/s10637-012-9854-2

DO - 10.1007/s10637-012-9854-2

M3 - Article

C2 - 22821172

AN - SCOPUS:84879555723

VL - 31

SP - 285

EP - 292

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 2

ER -